Intra-Peritoneal Administration of Genetic Therapies: promises and pitfalls

Evans, T.R.J. and Keith, W.N. (2004) Intra-Peritoneal Administration of Genetic Therapies: promises and pitfalls. Minerva Ginecologica, 56(6), pp. 529-538.

Full text not currently available from Enlighten.

Publisher's URL:


Rapid advances in our understanding of the molecular basis of cancer development and progression over the past 3 decades have led to the design of new potential cancer therapies based on the expression of introduced genes into a tumor or its host. In an attempt to overcome the limitations of direct intratumoral administration of genetic therapies in patients with advanced malignant disease, loco-regional routes of delivery have been explored including the intraperitoneal route. This review highlights the potential of replication-competent oncolytic viruses, virus-mediated gene replacement, and gene-directed enzyme-prodrug strategies, as novel cancer therapies. The potential of exploiting the selectivity of the telomerase gene within cancer cells to develop gene therapy strategies is discussed and the promises and pitfalls in translating these novel therapeutics from the laboratory to the clinic are reviewed.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Evans, Professor Jeff and Keith, Professor Nicol
Authors: Evans, T.R.J., and Keith, W.N.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QH Natural history > QH426 Genetics
R Medicine > RG Gynecology and obstetrics
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Minerva Ginecologica

University Staff: Request a correction | Enlighten Editors: Update this record